Worldquant Millennium Advisors LLC Boosts Stake in DaVita Inc. (NYSE:DVA)

Worldquant Millennium Advisors LLC lifted its stake in shares of DaVita Inc. (NYSE:DVA - Free Report) by 121.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 37,489 shares of the company's stock after acquiring an additional 20,548 shares during the period. Worldquant Millennium Advisors LLC's holdings in DaVita were worth $6,146,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Harvard Management Co. Inc. acquired a new stake in shares of DaVita during the 2nd quarter worth about $55,115,000. FMR LLC boosted its position in DaVita by 659.9% during the third quarter. FMR LLC now owns 177,406 shares of the company's stock worth $29,082,000 after acquiring an additional 154,061 shares during the last quarter. Glenmede Trust Co. NA grew its stake in DaVita by 731.6% in the 3rd quarter. Glenmede Trust Co. NA now owns 123,269 shares of the company's stock worth $20,207,000 after acquiring an additional 108,446 shares during the period. Point72 Asset Management L.P. acquired a new position in DaVita in the 2nd quarter valued at $9,615,000. Finally, KBC Group NV lifted its stake in shares of DaVita by 27.3% during the 3rd quarter. KBC Group NV now owns 313,519 shares of the company's stock worth $51,395,000 after purchasing an additional 67,250 shares during the period. Hedge funds and other institutional investors own 90.12% of the company's stock.

DaVita Trading Down 0.7 %

DaVita stock traded down $1.12 during midday trading on Friday, reaching $160.25. The stock had a trading volume of 506,762 shares, compared to its average volume of 744,634. The stock's 50-day simple moving average is $158.58 and its 200 day simple moving average is $150.23. DaVita Inc. has a twelve month low of $103.40 and a twelve month high of $169.51. The company has a debt-to-equity ratio of 15.78, a quick ratio of 1.33 and a current ratio of 1.37. The stock has a market capitalization of $13.14 billion, a PE ratio of 17.29, a price-to-earnings-growth ratio of 0.92 and a beta of 0.90.

DaVita (NYSE:DVA - Get Free Report) last issued its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The firm had revenue of $3.26 billion for the quarter, compared to analysts' expectations of $3.25 billion. During the same quarter in the previous year, the firm posted $2.85 EPS. The firm's revenue for the quarter was up 4.6% compared to the same quarter last year. Analysts expect that DaVita Inc. will post 9.71 EPS for the current year.

Insider Activity

In other news, CEO Javier Rodriguez sold 9,881 shares of the stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $162.85, for a total value of $1,609,120.85. Following the completion of the sale, the chief executive officer now owns 887,835 shares in the company, valued at approximately $144,583,929.75. This trade represents a 1.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 2.00% of the company's stock.

Analysts Set New Price Targets

DVA has been the subject of a number of recent analyst reports. Truist Financial lifted their price objective on DaVita from $165.00 to $175.00 and gave the company a "hold" rating in a research report on Monday, October 7th. Barclays lifted their price target on DaVita from $150.00 to $164.00 and gave the company an "equal weight" rating in a report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $161.80.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.